ABOS

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing disease-modifying treatments for Alzheimer's disease and other neurodegenerative conditions. Headquartered in Charlottesville, Virginia, the company was founded in 2019 and concentrates on targeting toxic soluble amyloid-beta oligomers (AβOs), which it believes are a primary cause of Alzheimer's pathology. Acumen's lead product candidate, ACU193, is a humanized monoclonal antibody designed to selectively target AβOs while avoiding amyloid plaques. The company initiated a Phase 1 clinical trial for ACU193 in 2021 and subsequently advanced into Phase 2 studies evaluating the treatment in patients with early Alzheimer's disease. Acumen's approach differentiates itself from traditional anti-amyloid therapies by specifically targeting soluble oligomers rather than insoluble plaques. The company completed its initial public offering in July 2023, raising approximately $102 million to fund continued clinical development and operations. As of its latest disclosures, Acumen employs approximately 40 people and maintains research collaborations with academic institutions. The company does not yet generate product revenue and remains focused entirely on advancing its clinical pipeline through development milestones, with ACU193 representing its primary value driver as it progresses through mid-stage clinical testing.